InvestSMART

Algorae Pharmaceuticals Limited (ASX:1AI)

ALERT: Price-sensitive ASX Announcement for 1AI
Current share price for 1AI : $0.012 0 (0%)+
Announcement
Release
3 Jul 2026 9:03AM
Price at Release
$0.012
Full Release
download
Summary
Algorae Pharmaceuticals Limited announced positive results from a preclinical validation study of its AlgoraeOS v2 drug-combination prediction platform, conducted in collaboration with the Victorian Centre for Functional Genomics at the Peter MacCallum Cancer Centre. The study demonstrated that AlgoraeOS v2 has an improved predictive power over its predecessor, AlgoraeOS v1, by identifying a higher proportion of synergistic drug combinations. The validation involved assessing 24 drug combinations with CBD across four cancer cell models, resulting in approximately 10,000 data points. The use of multiple drug interaction models and the introduction of uncertainty metrics enhanced the robustness of the predictions. The company plans to further develop the identified drug combinations and expand its multi-anchor combination pipeline.
Key Points
  • Positive preclinical results from the AlgoraeOS v2 validation at Peter Mac
  • AlgoraeOS v2 demonstrated improved predictive power over AlgoraeOS v1
  • 24 drugs combined with CBD tested across four cancer cell models
  • 10,000 data points generated from the study
  • Validation confirms enhancements to AlgoraeOS improve predictive accuracy
  • Potential drug combinations identified for future research
  • Use of four drug interaction models to assess synergy
  • Introduction of uncertainty metrics to improve prediction accuracy
  • Algorae aims to develop and assess identified synergistic combinations
  • Focus on expanding the drug-combination pipeline
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.